1. Home
  2. Live Updates
  3. Common terminology criteria

Live Breaking News & Updates on Common Terminology Criteria|Page 4

Stay updated with breaking news from Common terminology criteria. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Lantheus and POINT Biopharma Announce Positive Topline Results from Pivotal SPLASH Trial in Metastatic Castration-Resistant Prostate Cancer

Phase 3 SPLASH study of 177Lu-PNT2002 demonstrated statistically significant improvement in radiographic progression-free survival BEDFORD, Mass., and INDIANAPOLIS, Dec. 18, 2023 December. ....

United States , United Kingdom , New Jersey , Eli Lilly , Neil Fleshner , Daniel Pearlstein , Kim Chi , Mark Kinarney , Exchange Commission , Company Lilly , Lantheus Holdings Inc , Biopharma Global Inc , American Cancer Society , Lantheus Holdings , Medical Oncologist , New Drug Application , Common Terminology Criteria , Adverse Events , North America , Chief Medical Officer , Jean Claude Provost , Fast Track , Risk Factors , Annual Reports , Quarterly Reports , Recommendation Statement ,

Why is Prostate Cancer Focused Lantheus (LNTH) Stock Trading Lower Today? - Lantheus Holdings (NASDAQ:LNTH), POINT Biopharma Global (NASDAQ:PNT)

Lantheus Holdings Inc (NASDAQ: LNTH) and POINT Biopharma Global Inc (NASDAQ: PNT) reported topline data from pivotal Phase 3 SPLASH trial of 177Lu-PNT2002 in metastatic castration-res ....

Biopharma Globalinc , Lantheus Holdings Inc , New Drug Application , Common Terminology Criteria , Adverse Events ,

Lantheus and POINT Biopharma Announce Positive Topline Results from Pivotal SPLASH Trial in ...

Phase 3 SPLASH study of177Lu-PNT2002 demonstrated statistically significant improvement in radiographic progression-free survival (rPFS) ....

United States , United Kingdom , New Jersey , Mark Kinarney , Kim Chi , Eli Lilly , Daniel Pearlstein , Neil Fleshner , Exchange Commission , Biopharma Global Inc , Lantheus Holdings Inc , Company Lilly , American Cancer Society , Lantheus Holdings , Medical Oncologist , New Drug Application , Common Terminology Criteria , Adverse Events , North America , Chief Medical Officer , Jean Claude Provost , Fast Track , Risk Factors , Annual Reports , Quarterly Reports , Recommendation Statement ,

Adverse Effects Impact Treatment Selection for VEGF-Targeted Oral TKIs in Metastatic RCC

Axitinib, cabozantinib, and lenvatinib are first-line treatment options. ....

United States , University Of Washington Medical Center , Jina Yun , Dane Fritzsche , Dihydropyridine Ccbs , Vegftargeted Tkis , Van Sebille , Cindy Nguyen , Axitinib Inlyta , Eisai Co Ltd , Exelixis Inc , Exelixis Access Services , European Society For Therapeutic Radiology , Oncology Society , Fred Hutchinson Cancer Center , National Comprehensive Cancer Network , Eisai Inc , Bristol Myers Squibb , Spanish Academy Of Dermatology , National Cancer Institute , Spanish Society Of Medical Oncology , Pfizer Inc , International Cardio , European Society Of Cardiology , European Surgical Association , Johnson Consumer Inc ,

Updated Data from the BRUIN Phase 1/2 Study of Pirtobrutinib in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma Presented at the 2023 ASH Annual Meeting

/PRNewswire/ Eli Lilly and Company (NYSE: LLY) today announced updated clinical data from the international Phase 1/2 BRUIN trial of pirtobrutinib, a. ....

United States , Eli Lilly , Prnewswire Eli Lilly , Kyle Owens , David Hyman , Joe Fletcher , Matthews Davids , Dana Farber Cancer Institute , American Society Of Hematology , Lilly United States , Laboratory Abnormalities , Exchange Commission , American Society , Annual Meeting , Dana Farber Cancer , Common Terminology Criteria , Adverse Events , Primary Malignancies , Fetal Toxicity , Patients Who Received , Special Populations , Renal Impairment , Prescribing Information , Patient Information , Private Securities Litigation Reform Act , United States Securities ,